Immunotherapy

Tabelecleucel Shows High Response Rates in Patients with EBV-Associated Posttransplant Lymphoma Refractory to Rituximab

Walter Alexander

October 2018, Vol 8, No 10 - Immunotherapy

Patients with Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorders (PTLD) who do not respond to first-line rituximab (Rituxan) therapy are extremely difficult to manage, said Susan E. Prockop, MD, Pediatric Oncologist, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2018 European Hematology Association Congress. [ Read More ]

Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC

Charles Bankhead

May 2018, Vol 8, No 5 - Immunotherapy

Almost 66% of patients who had previously received treatment for metastatic co­lorectal cancer (mCRC) and DNA mismatch repair deficiency (dMMR) derived clinical benefit from monotherapy with nivolumab (Opdivo), long-term follow-up from a prospective clinical trial showed. After a median follow-up of almost 2 years, 34% of 74 evaluable patients had objective responses, including 7 complete responses. [ Read More ]

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

Meg Barbor, MPH

April 2018, Vol 8, No 4 - Immunotherapy, Survivorship

Because of the novel mechanisms of action of immunotherapies, extended treatment period, and unique toxicities, cancer treatment with immunotherapy warrants special consideration from a survivorship standpoint, suggested Katy K. Tsai, MD, Clinical Instructor, Division of Hematology/Oncology, University of California, San Francisco (UCSF), at the 2018 Cancer Survivorship Symposium. [ Read More ]

Switching on the Light: A Model Immunotherapy Program for Oncology Practices

Gail Thompson

February 2018, Vol 8, No 2 - Immunotherapy

Immunotherapy is one of the hottest concepts in oncology care. Also called biologic therapy, this type of cancer treatment boosts the body’s own natural defenses to fight cancers. Ann M. McGreal, RN, OCN, Oncology Nurse Clinician, and Sigrun Hallmeyer, MD, Senior Executive Director, Advocate Medical Group, Park Ridge, IL, shared their experience with immunotherapy at the ACCC National Oncology Conference in October 2017 in Nashville. [ Read More ]